Sugi Predict

Sugi Predict / Compounds / SCHEMBL526319

SCHEMBL526319

SCHEMBL526319

COCc1ccncc1Br

nearest known ligand 0.45

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CYP11B2 P19099 3/20 0.45
▸ CYP11B1 P15538 2/20 0.45
▸ PARP1 P09874 1/20 0.36
▸ AOC1 P19801 6/20 0.35
▸ AOC3 Q16853 6/20 0.35
▸ HTT P42858 2/20 0.35
▸ NPSR1 Q6W5P4 2/20 0.35
▸ MEN1 O00255 1/20 0.35
▸ ALDH1A1 P00352 1/20 0.35
▸ TSHR P16473 1/20 0.35
▸ KMT2A Q03164 1/20 0.35
▸ LOXL2 Q9Y4K0 1/20 0.34
▸ LMNA P02545 1/20 0.34
▸ SLC6A2 P23975 2/20 0.33
▸ SLC6A4 P31645 2/20 0.33
▸ SLC6A3 Q01959 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA9 Q16790 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15822832 0.84 CYP11B1 (0.42) CYP11B2CYP11B1AOC1AOC3HTT
SCHEMBL23480267 0.81 CYP11B2 (0.49) CYP11B2CYP11B1AOC1AOC3HTT
SCHEMBL28488560 0.81 CA12 (0.36) CYP11B2CYP11B1PARP1AOC1AOC3
SCHEMBL20519350 0.81 PARP1 (0.35) CYP11B2CYP11B1PARP1AOC1AOC3
SCHEMBL14992538 0.79 AOC1 (0.37) CYP11B2CYP11B1PARP1AOC1AOC3
SCHEMBL26442736 0.78 CYP11B2 (0.46) CYP11B2CYP11B1AOC1AOC3HTT
SCHEMBL31651759 0.77 — —
SCHEMBL793614 0.77 — —
SCHEMBL21383722 0.77 CA12 (0.36) PARP1AOC1AOC3TSHRCA12
SCHEMBL8357660 0.76 AOC1 (0.59) CYP11B2CYP11B1AOC1AOC3MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 104 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4696316-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2026-02-18 — — EP disclosed
US-20260042740-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-12 — — US disclosed
EP-4054719-B1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2026-02-11 — — EP disclosed
US-20250388598-A1 RAS INHIBITORS WILMINGTON TRUST, NATIONAL ASSOCIATION, AS AGENT 2025-12-25 — — US disclosed
US-20250368661-A1 RAS INHIBITORS REVOLUTION MEDICINES INC (US) 2025-12-04 — — US disclosed
EP-4656201-A2 RAS INHIBITORS Revolution Medicines, Inc. (US) 2025-12-03 — — EP disclosed
US-12384750-B2 Ras inhibitors Revolution Medicines, Inc. (US) 2025-08-12 — — US disclosed
US-20250197368-A1 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS DRAIG THERAPEUTICS LTD. (GB) 2025-06-19 — — US disclosed
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS Revolution Medicines, Inc. 2025-06-19 — — US disclosed
CN-115873020-B RAS inhibitors 锐新医药公司 2025-06-13 — — CN disclosed
WO-2014179186-A1 ALDOSTERONE SYNTHASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-11-06 — — WO disclosed
US-20140323468-A1 ALDOSTERONE SYNTHASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-30 — — US disclosed
US-20140323468-A1 ALDOSTERONE SYNTHASE INHIBITORS BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2014-10-30 — — US disclosed
US-20140148453-A1 SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2014-05-29 — — US disclosed
US-20140148453-A1 SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2014-05-29 — — US disclosed
US-20140148453-A1 SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY 2014-05-29 — — US disclosed
US-20130143863-A1 NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2013-06-06 — — US disclosed
EP-2598481-A1 SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS Bristol-Myers Squibb Company (US) 2013-06-05 — — EP disclosed
WO-2012015723-A1 SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-02 — — WO disclosed
WO-2012015723-A1 SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS BRISTOL-MYERS SQUIBB COMPANY (US) 2012-02-02 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (9 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250368661-A1 RAS INHIBITORS KRAS, NRAS, HRAS CYP11B2 4359/4885CYP11B1 4095/4885PARP1 2382/4885
US-20260042740-A1 RAS INHIBITORS KRAS, NRAS, HRAS CYP11B2 3708/4885CYP11B1 3080/4885PARP1 3300/4885
US-20250195521-A1 USE OF SOS1 INHIBITORS TO TREAT MALIGNANCIES WITH SHP2 MUTATIONS SOS1, PPM1D, PTPN1 CYP11B2 4486/4885CYP11B1 4102/4885PARP1 4576/4885
US-20130143863-A1 NEW BICYCLIC DIHYDROISOQUINOLINE-1-ONE DERIVATIVES CYP11B1, CYP11B2, HSD11B1 CYP11B2 2/4885CYP11B1 1/4885PARP1 3649/4885
US-20140148453-A1 SULFONAMIDE COMPOUNDS USEFUL AS CYP17 INHIBITORS SULT1A1, SULT2A1, SULT1E1 CYP11B2 38/4885CYP11B1 22/4885PARP1 2588/4885
US-20250197368-A1 2-OXO-DIHYDROQUINOLINE-3-CARBOXAMIDE DERIVATIVES AS GABA TYPE A RECEPTOR MODULATORS GABRA2, GABRA3, GABRB2 CYP11B2 395/4885CYP11B1 595/4885PARP1 3065/4885
US-20140323468-A1 ALDOSTERONE SYNTHASE INHIBITORS CYP11B1, CYP21A2, REN CYP11B2 4/4885CYP11B1 1/4885PARP1 1917/4885
US-20250388598-A1 RAS INHIBITORS KRAS, NRAS, G3BP2 CYP11B2 1675/4885CYP11B1 1047/4885PARP1 4002/4885
US-12384750-B2 Ras inhibitors KRAS, NRAS, HRAS CYP11B2 4359/4885CYP11B1 4095/4885PARP1 2382/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.